Can These Stocks Deliver Good Returns? Aegerion Pharmaceuticals, Inc. (AEGR), Unilife Corp (UNIS) and Oncothyreon Inc (ONTY)
New York, NY – GDP INSIDER – 05/18/2014.
This article discusses three companies: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), Unilife Corp (NASDAQ:UNIS) and Oncothyreon Inc (USA) (NASDAQ:ONTY)
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) declined on Friday with the stock hitting a new one year low of $19.10 before recovering to $19.28 by the end of its trading session, down 5.61% or $1.14 with more than 1.739 million shares changing hands compared to its three month average trading volume of 0.549 million. The biopharmaceutical company has been declining steadily for most of the last 12 months with the stock down 42%, compared to the S&P 500 which is up 12.61% for the same period. With the stock now down over 7.53% over the last five days and RSI at 17.07, it is starting to look like a very good potential purchase, making it a buy at this time.
Unilife Corp (NASDAQ:UNIS) suffered a decline of sixteen cents during Friday’s trading session to close the day at $2.99, a 5.08% decline in value from its previous closing price of $3.15 on light trading volume of 0.596 million, compared to its three month average trading volume of 1.13 million. Despite the decline, the stock is still trading 49.50% above its 52 week low of $2.00. The drug delivery company has lost a total of 11% since the beginning of the year and has been mostly underperforming the S&P 500. The S&P 500 has gained 3.10% over the same period. With RSI of 32.89 and one year target estimate of $8.59, the stock has plenty of upside potential, making it a hold with a view to buy.
Oncothyreon Inc (USA) (NASDAQ:ONTY) had a huge day on Friday with the stock gaining 20.30% or $0.41 to close the day at $2.43. The big jump came after the company entered into a Securities Exchange Agreement with Biotechnology Value Fund, L.P., on Thursday. Volume also was up in Friday’s trading session to 31.833 million shares from the 1.08 million daily average. It has products in various stages of the clinical trial process. If those pass trials and move to the next phases, the stock can go higher. The stock has been having a very strong year so far, with the stock up 28%, but is trading uncertainly at the moment, as its RSI is at 73.74 making investors nervous. With its direction uncertain at this time, it is best to hold or profit-take at this price.
About Ultimate Stock Alerts
UltimateStockAlerts.com covers NASDAQ and NYSE listed companies that are overlooked by Wall Street. Investors can choose to receive trading strategies via text message (SMS) or email. To receive free text message alerts text the word ULTIMATE to 555888 from your cell phone. For more information visit www.UltimateStockAlerts.com
Disclosure: UltimateStockAlerts.com is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit www.UltimateStockAlerts.com website, for complete risks and disclosures.